From scientific innovation to clinical adoption
Marketing expertise & go-to-market strategy for diagnostics and clinical decision support solutions.
Your teams are developing a promising scientific innovation, from initial project structuring through to market entry and commercialization.
Early on, critical questions arise: what is the true value proposition? Which clinical uses should be prioritized? Which markets should be addressed first? How can a clear and credible narrative be built for investors, partners and intended users?
CGB Nexus supports teams throughout this entire journey, turning scientific innovation into a clear, differentiated and aligned strategy that builds investor confidence, creates coherent market traction and enables sustainable clinical adoption.
Get a Strategic Assessment (30 min)
No commitment — confidential exchange
See what they say about CGB Nexus
Catherine’s support was key in defining our future company’s positioning, structuring our strategy and strengthening our materials. Her market analysis and message clarity made a real difference.
- Radiation oncologist supported by the PSCC for an entrepreneurial project.
A great technology alone is not enough to convince the market.
The founders and executives I support often share the same observations:
- Strategic fundamentals are not clearly defined early on
- Messages remain too scientific for non-clinical decision-makers
- Differentiation remains difficult in an already crowded diagnostic landscape.
- The go-to-market plan remains fragmented and hard to execute day to day
- Marketing and sales teams operate under pressure, without a clear framework
As a result, a long gap often emerges between scientific proof and real-world adoption by clinicians, care centers and partners.
If this sounds familiar, you’re exactly where my clients usually are when we start working together.
For innovators who want their solutions anchored in clinical practice.
I support teams developing innovations in healthcare and life sciences with one clear intention: to see their solutions used, prescribed and integrated into care pathways.
My clients notably include:
- Early-stage startups, scale-ups, and mature companies across oncology and life sciences.
- Teams developing molecular diagnostic tests including biomarker signatures, analytical platforms (NGS, digital pathology, bioinformatics), or clinical decision support solutions, often AI-based.
- Organizations preparing a European market entry or refining their European go-to-market strategy.
Whether you are shaping your development strategy, preparing a launch, an indication extension or a repositioning, the goal remains the same: to make your value obvious to every stakeholder.
From product vision to an actionable go-to-market plan
My role is to connect three worlds: Science, the market and the players who truly decide on adoption.
I work across three complementary pillars:
Clarifying the value proposition
Gaining a deep understanding of your data, clinical promise and constraints. Formulating a clear value proposition for each audience: clinicians, KOLs, hospital decision-makers, payers, industry partners, investors and patients. Highlighting what truly sets your solution apart in a saturated market.
Structuring the go-to-market strategy
Analyzing the competitive landscape and segment dynamics (France, Europe, United States). Prioritizing patient segments, countries, center types and first target sites. Structuring a clear 12–24 month roadmap: key milestones, sequences and decision points.
Turning strategy into concrete actions
Preparing the elements required for critical moments (launch, early adoption, commercial expansion, partnerships, fundraising). Designing campaigns and materials tailored to the healthcare sector. Equipping your medical and commercial teams with consistent, easy-to-use messaging for the field.
Selected case studies
How we work
Flexible engagement models, tailored to your priorities and stage of development.
Choose the level of support that best fits your needs, from focused strategic input to hands-on execution.
Project Based Engagements
For strategic initiatives, launches, campaigns or market analyses.
Retainer / Fractional Marketing Leadership
Part-time strategic and operational support (Head of Marketing / CMO). Ideal for startups and scale-ups needing expert leadership.
Workshops & Training
Strategic workshops to align teams and decision-making. Value proposition, messaging, GTM strategy, sales enablement.
CGB Nexus, at the crossroads of diagnostics, marketing and international markets.
I am Catherine Gerbon, founder of CGB Nexus Consulting.
For more than twenty years, I have worked in oncology diagnostics and life sciences with one guiding focus: turning scientific innovation into sustainable market success.
I have held marketing and business leadership roles across organizations ranging from startups to large international companies, including Ipsogen, QIAGEN, HalioDx, Veracyte, Myriad Genetics and Eurobio Scientific, with strong international exposure.
These experiences taught me to:
- Navigate between clinicians, biologists, hospital leadership and industrial stakeholders
- Translate complex data into clear messages without distorting the science.
- Build realistic plans that teams can successfully execute over time.
CGB Nexus carries this ambition: connecting ideas, people and data to give the most promising healthcare projects a clear direction.
What they say
Thanks to Catherine’s analysis, we achieved a very clear and structured synthesis of our constraints. The quality of her expertise and her professional responsiveness helped define priorities and critical steps for the strategic development of our oncology diagnostic.
- Oury Chetboun, CEO – SEEKYO Therapeutics
Catherine helped us clarify several key aspects of our strategy: relevant patient sub-population targeting, market prioritization and positioning of our early colorectal cancer screening solution. Her deep understanding of diagnostic challenges and her ability to rapidly analyze options and surface key decisions brought real value to our work. This supported decision-making and set solid foundations for the continuation of the project.
- Agnès Martinec, COO – CYBERNA
Catherine brought real added value by consolidating our marketing strategy with a strong understanding of our field. Her support was also decisive at the operational level, especially in the production and structuring of our marketing materials.
- Arnaud Cutivet, CEO – MSInsight
Thanks to the speed and quality of her work, Catherine helped Cyberna clarify its positioning and market priorities. Her expertise in oncology diagnostics strongly reinforced the relevance of the support delivered in 2025 in partnership with Eurobiomed.
- Laurent Garnier, Project Manager – Eurobiomed
Beyond her market access expertise, Catherine
demonstrated exceptional listening skills and insightful understanding of the Kitech, medtech-deeptech project, and provided a truly strategic vision. She integrated our priorities and gave us a go-to-market roadmap outlining the key next steps to strengthen the strategic maturity of our project.
- Dr Gilles Shutz, Nephrologist and Ki'Tech cofounder.
Let’s discuss your project
Are you defining your development strategy, preparing a launch, or an indication expansion in oncology diagnostics or clinical decision support solutions?
A 30-minute conversation is enough for me to understand your challenges, position your project and identify your first marketing priorities.